Validated research tool to be used to predict disease severity and individual therapeutic response to COVID-19 in aid of rapid vaccine and drug development.
Sixfold Bioscience and Medicines Discovery Catapult (MDC) awarded Innovate UK grant to pursue ground-breaking project.
Today, Medicines Discovery Catapult (MDC) announce the rapid expansion of its Biosamples supply network, creating one of the largest virtual biobanks worldwide accessible to life science innovators.
Medicines Discovery Catapult announce that it has been awarded government seedcorn funding; provided through UK Research and Innovation’s flagship £236m Strength in Places Fund, along with project partner Cheshire & Warrington Local Enterprise Partnership (LEP).
Cheshire East Council has welcomed the announcement on 4 August 2020, of £15.5 million of the Getting Building Fund for investment in schemes in Cheshire and Warrington.
The Alderley Park Lighthouse Lab, which was launched to rapidly expand COVID-19 testing capacity, has processed more than 1 million test samples since opening.
Consortia are enabling drug discovery in areas that individual organizations are unable to support alone because of the high risk or the need to pool information.
The Psychiatry Consortium is again seeking project proposals which focus on the validation of novel molecular drug-targets.
This week the Medicines Discovery Catapult has welcomed three new Board Members.
Medicines Discovery Catapult, Retrogenix and Peak Proteins collaborate to identify target receptors for COVID-19.
See how we can help support you with your next drug discovery project.
Speak to us